1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. Syk

Syk

Syk (Spleen tyrosine kinase) is an enzyme which in humans is encoded by the SYK gene. Syk, along with Zap-70, is a member of the Syk family of tyrosine kinases. Syk is known to have a crucial role in adaptive immune receptor signalling. Recent reports indicate that Syk also mediates other, unexpectedly diverse biological functions, including cellular adhesion, innate immune recognition, osteoclast maturation, platelet activation and vascular development. Syk is activated by C-type lectins and integrins, and activates new targets, including the CARD9-Bcl-10-MALT1 pathway and the NLRP3 inflammasome. Syk has a crucial role in autoimmune diseases and haematological malignancies.

Syk Related Products (25):

Cat. No. Product Name Effect Purity
  • HY-15968
    Entospletinib Inhibitor 99.86%
    Entospletinib (GS-9973) is an orally bioavailable, selective Syk inhibitor with an IC50 of 7.7 nM.
  • HY-12067
    R406 Inhibitor
    R406 is a competitive Syk inhibitor for ATP binding with a Ki of 30 nM, potently inhibits Syk kinase activity in vitro with an IC50 of 41 nM, measured at an ATP concentration corresponding to its Km value.
  • HY-15999
    Cerdulatinib Inhibitor 99.00%
    Cerdulatinib (PRT062070) is a selective Tyk2 inhibitor with an IC50 of 0.5 nM. Cerdulatinib (PRT062070) also is a dual JAK and SYK inhibitor with IC50s of 12, 6, 8 and 32 for JAK1, 2, 3 and SYK, respectively.
  • HY-100867A
    TAK-659 hydrochloride Inhibitor 99.69%
    TAK-659 hydrochloride is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC50 of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 hydrochloride induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL).
  • HY-13038
    Fostamatinib Disodium Inhibitor 99.88%
    Fostamatinib Disodium (R788 Disodium), a prodrug of the active metabolite R406, is a potent Syk inhibitor with IC50 of 41 nM.
  • HY-12657
    Syk-IN-1 Inhibitor 99.18%
    Syk-IN-1 (compound 4) is a potent Syk inhibitor, with an IC50 of 35 nM.
  • HY-112390A
    Syk Inhibitor II Inhibitor 98.05%
    Syk Inhibitor II is a potent, high selective and ATP-competitive Syk inhibitor with an IC50 of 41 nM. Syk Inhibitor II inhibits 5-HT release from RBL-cells with an IC50 of 460 nM. Syk Inhibitor II shows less potent against other kinases and has anti-allergic effect.
  • HY-15999A
    Cerdulatinib hydrochloride Inhibitor 99.54%
    Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC50s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and Tyk2, JAK1, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies.
  • HY-13518
    Piceatannol Inhibitor 98.10%
    Piceatannol is a selective inhibitor of protein tyrosine kinase Syk.
  • HY-13038A
    Fostamatinib Inhibitor 99.20%
    Fostamatinib (R788), a prodrug of the active metabolite R406, is a potent Syk inhibitor with IC50 of 41 nM.
  • HY-11108
    R406 free base Inhibitor 99.69%
    R406 free base is a potent Syk inhibitor with IC50 of 41 nM, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3.
  • HY-15323
    PRT062607 Hydrochloride Inhibitor 98.90%
    PRT062607 Hydrochloride (P505-15 Hydrochloride) is a highly specific and potent inhibitor of purified Syk (IC50 1-2 nM).
  • HY-13038B
    Fostamatinib disodium hexahydrate Inhibitor 99.92%
    Fostamatinib disodium hexahydrate (R788 disodium hexahydrate), a prodrug of the active metabolite R406, is a potent Syk inhibitor with IC50 of 41 nM.
  • HY-109091
    Lanraplenib Inhibitor 98.22%
    Lanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib (GS-9876) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.
  • HY-14985
    BAY 61-3606 dihydrochloride Inhibitor 98.76%
    BAY 61-3606 dihydrochloride is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM an IC50 of 10 nM. BAY 61-3606 dihydrochloride reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell. BAY 61-3606 dihydrochloride induces a large decrease of Syk phosphorylation in K-rn cell lysates. Bay 61-3606 dihydrochloride sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells.
  • HY-103018
    Gusacitinib Inhibitor 99.41%
    Gusacitinib (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 values of 5-46 nM. Gusacitinib has anti-cancer activity in both solid and hematological tumor types.
  • HY-16902
    RO9021 Inhibitor 98.89%
    RO9021 is an orally bioavailable, novel ATP-competitive inhibitor of SYK, with an average IC50 of 5.6 nM.
  • HY-78263
    MNS Inhibitor
    MNS (NSC 170724), the beta-nitrostyrene derivative, is a potent tyrosine kinase inhibitor and a broad-spectrum antiplatelet agent. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC50 values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS inhibits Src, Syk, and FAK with IC50 of 27.3, 2.8, and 97.6 μM, respectively.
  • HY-12974
    PRT-060318 Inhibitor 99.50%
    PRT-060318 (PRT318) is a novel selective inhibitor of the tyrosine kinase Syk with an IC50 of 4 nM.
  • HY-16420
    R112 Inhibitor 99.95%
    R112 is an ATP-competitive inhibitor of Syk kinase with a Ki of 96 nM. R112 inhibits Syk kinase activity with an IC50 of 226 nM.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.